Cabotegravir

Overview

Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 ( OAT1 / OAT3 ) inhibitor with IC 50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIV ADA , OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase ( UGT ) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS.

Application

Products | Products > Disease Areas > Viral Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Signaling Pathways > OAT | Products > Signaling Pathways > HIV | Products > Signaling Pathways > HIV Integrase

Product Information

• Catalog No.: HY-15592
• CAS No.: 1051375-10-0
• Molecular Formula: C19H17F2N3O5
• Molecular Weight: 405.35
• Purity: 99.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1.67 mg/mL (4.12 mM); Clear solution
• Availability: In-stock

Source

Original product source